ブログ
David Latham, Matthew Allen and Charlie Dean use a case study of a reusable electromechanical autoinjector to outline the novel product development approach needed to achieve better outcomes for patients, pharma, payers and the planet.
The stakeholder needs in drug delivery device development are continually evolving, resulting in an increasing breadth of variables at play and the number of tools required. Having a clear product development roadmap created with iterative design inputs from multiple disciplines is key to determining the optimal path to satisfy these conflicting requirements. This succeeds by elevating conventional product development with the integration of business strategy, product cost, environmental product stewardship and patient-centric design. To unlock this potential, a culture of smart risk-taking is also necessary. Discovering dead ends early on and tackling the highest risk areas first gives the best development value to investment ratio.
To read the full article, originally published by ONdrugDelivery, please download below.
Please watch the following video showcasing the two Bamboo electromechanical autoinjector variants featured in the article above.
専門家
David is a programme manager and has worked in healthcare product development since 2007. He is a Chartered Mechanical engineer by background having graduated from University of Oxford with a Masters degree in Engineering Science.
Charlie is the Head of Sustainable Medical Technology with expertise in mechanical design and analytical methods in medical device development. He is a LCA practitioner who leads evaluation and design of medical products to drive environmental impact mitigation activities and for the circular economy.
